Recent News

• 04.21.2025 - Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
• 04.21.2025 - Cassava Announces Retirement of Chief Medical Officer, Dr. Jim Kupiec, and Appointment of Dr. Jack Moore as Senior Vice President, Clinical Development
• 03.25.2025 - Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
• 03.25.2025 - Cassava Sciences Reports Topline Phase 3 REFOCUS-ALZ Data
• 03.03.2025 - Cassava Sciences Reports 2024 Financial Results and Provides Business Update
• 02.27.2025 - Cassava Sciences Licenses Simufilam Method of Treatment Patent
• 02.27.2025 - Cassava Sciences Licenses Simufilam Method of Treatment Patent
• 01.07.2025 - Cassava Sciences Provides a Business Update
• 01.07.2025 - Cassava Sciences Provides a Business Update

Recent Filings

• 04.14.2025 - ARS Annual Report to Security Holders
• 04.14.2025 - DEF 14A Other definitive proxy statements
• 04.03.2025 - PRE 14A Other preliminary proxy statements
• 03.25.2025 - 8-K Current report
• 03.25.2025 - EX-99.1 EX-99.1
• 03.11.2025 - 8-K Current report
• 03.03.2025 - 8-K Current report
• 03.03.2025 - 10-K Annual report [Section 13 and 15(d), not S-K Item 405]
• 03.03.2025 - EX-99.1 EX-99.1
• 02.27.2025 - EX-99.1 EX-99.1